MENLO PARK, Calif.--(BUSINESS WIRE)--HALO Precision Diagnostics (“HALO”), the leader in early disease detection using precision diagnostics, today announced the appointment of John Craighead, Ph.D., as chief operating officer and chief financial officer.
“John’s deep life science industry experience and business and financial acumen will serve HALO well as we pursue our life-saving mission,” said Michael Uhl, HALO chief executive officer. “Together we will make personalized medicine more accessible and affordable, transforming how patients and their doctors get ahead and stay ahead of deadly diseases.”
HALO, through a growing network of owned and partner clinics and the company’s proprietary precision diagnostics platform, integrates advanced imaging with molecular diagnostics to deliver comprehensive clinical insights for early disease detection and treatment. The company has clinically validated care pathways for prostate cancer, breast cancer, and cardiovascular disease, as well as plans for neurodegenerative and other life-threatening diseases.
“HALO has assembled an impressive team spanning business, healthcare, and technology, and I am excited to join in the mission to save lives and expand access to precision diagnostics,” said Craighead. “HALO's groundbreaking approach to early disease detection presents an incredible opportunity to make a profound impact and improve healthcare.”
Craighead has more than 20 years of life sciences and financial services experience, recently serving as chief financial officer and head of Corporate Development at Elpiscience. Earlier, he was vice president of Strategy, Corporate Development and Investor Relations at GRAIL. He also held leadership roles at Sanofi, Atara Biotherapeutics, Lehman Brothers, and Human Genome Sciences.
Craighead is a National Science Foundation Fellowship recipient. He received his doctorate in cell biology from Scripps Research, La Jolla, California and a bachelor’s degree in chemistry and molecular biology from St. Olaf College, Northfield, Minnesota.
About HALO Precision Diagnostics
HALO Precision Diagnostics is the leader in early disease detection using precision diagnostics. The company integrates advanced imaging with molecular diagnostics to deliver comprehensive clinical insights for early disease detection and to efficiently guide diagnosis and treatment for patients and physicians. With clinically validated care pathways dedicated to prostate cancer, breast cancer, cardiovascular and neurodegenerative diseases, HALO is increasing early disease detection and transforming lives. HALO currently serves one million patients, a number expected to triple by 2024. For more information visit www.HALOdx.com.
